Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

CellRapeutics™ Anti-Aspergillus fumigatus CAR Cell Therapy Development Service

Online Inquiry

Background Services Required Starting Materials Workflow HCMV Antigen Types Advantages Case Study FAQs Contact Us

The development of anti-Aspergillus fumigatus CAR T-cell therapy represents a promising frontier in the fight against invasive aspergillosis (IA), a severe fungal infection particularly dangerous for immunocompromised patients. Current antifungal therapies often have limited efficacy, highlighting the urgent need for novel immune-enhancing strategies. Creative Biolabs provides a specialized CellRapeutics™ anti-Aspergillus fumigatus CAR cell therapy development service to develop effective therapeutics to assist in health safeguard.

Why We Need to Develop Anti-Aspergillus fumigatus CAR Cell Therapy

Invasive fungal infections (IFIs), particularly those caused by Aspergillus fumigatus, pose a significant threat to immunocompromised patients, leading to high mortality rates despite current antifungal treatments. The emergence of drug resistance and the systemic toxicities associated with existing therapies underscore an urgent unmet medical need for novel, targeted interventions. Anti-Aspergillus fumigatus CAR cell therapy represents a paradigm shift, offering a precise immunotherapeutic approach to combat these life-threatening infections by specifically targeting fungal pathogens, thereby enhancing patient outcomes and overcoming the limitations of conventional treatments.

Fig.1 Cells of the innate and adaptive immune systems interact with different morphotypes of Aspergillus fumigatus. (OA Literature) Fig.1 The interaction of Aspergillus fumigatus with innate and adaptive immune cells.¹

CellRapeutics™ Anti-Aspergillus fumigatus CAR Cell Therapy Development Service at Creative Biolabs

Creative Biolabs offers a comprehensive solution for developing cutting-edge CAR cell therapies specifically designed to target Aspergillus fumigatus. Our service provides you with custom-engineered immune cells, robust preclinical validation data, and expert guidance to advance your therapeutic candidates. We deliver highly specific and potent CAR constructs, engineered immune cells ready for preclinical evaluation, and comprehensive data packages to support your research and development milestones.

Required Starting Materials

Detailed information on the target Aspergillus fumigatus antigen(s) of interest (e.g., specific cell wall components, secreted proteins).
Source of immune cells (e.g., human peripheral blood mononuclear cells (PBMCs) or specific T cell/NK cell populations, if client-provided).
Specific project goals and desired CAR construct specifications.

Workflow: Developing Your Anti-Aspergillus fumigatus CAR Cell Therapy

Step 1

Target Antigen Identification & Validation

We begin by collaborating with you to identify and validate highly specific and accessible Aspergillus fumigatus antigens. This involves bioinformatic analysis, literature review, and in vitro screening to ensure optimal target selection for CAR recognition.

Step 2

CAR Construct Design & Optimization

Our experts design and optimize the chimeric antigen receptor (CAR) construct. This includes selecting the optimal single-chain variable fragment (scFv) for antigen binding, appropriate hinge and transmembrane domains, and intracellular signaling domains (e.g., CD3ζ, 4-1BB, CD28) to ensure robust activation and persistence of the engineered cells.

Step 3

Viral Vector Packaging & Production

We utilize advanced viral vector technologies (e.g., lentiviral or retroviral systems) to efficiently deliver the CAR gene into immune cells. Our state-of-the-art facilities ensure high-titer, high-quality viral vector production for efficient transduction.

Step 4

Immune Cell Engineering & Expansion

Patient-derived or donor immune cells (e.g., T cells, NK cells) are isolated, activated, and transduced with the optimized CAR construct. Following transduction, these CAR-expressing cells are expanded ex vivo to achieve the necessary cell numbers and purity for preclinical evaluation.

Step 5

Preclinical Evaluation (In Vitro & In Vivo)Evaluation

The modified CAR cells undergo rigorous preclinical testing to determine their potency, specificity, and safety. This includes in vitro assays (e.g., cytokine release, cytotoxicity, proliferation in response to A. fumigatus antigens) and in vivo studies using relevant fungal infection models to evaluate therapeutic potential.

Step 6

Quality Control & Regulatory Support

Throughout the process, stringent quality control measures are implemented to ensure the purity, viability, and functionality of the CAR cell product. We also provide comprehensive documentation and data packages to support your regulatory submissions.

Aspergillus fumigatus Antigen Types

Effective CAR cell therapy relies on the precise identification of target antigens. For Aspergillus fumigatus, potential antigens for CAR recognition include:

Cell Wall Components:
- β-glucans: Major structural polysaccharides crucial for fungal integrity and highly immunogenic.
- Chitin: Another primary structural polysaccharide, forming the fungal cell wall.
- Mannoproteins: Glycosylated proteins embedded in or secreted from the cell wall, often exposed on the fungal surface.
Secreted Proteins and Enzymes: Various proteins and enzymes released by A. fumigatus during infection, such as proteases or other virulence factors, which can be unique to the pathogen and accessible targets.

Attractive Advantages

Highly Targeted Therapy
Reduced Systemic Toxicity
Potential for Long-Term Protection
Overcome Antifungal Resistance

Case Study

Case Study One---

A leading academic research institution partnered with Creative Biolabs to develop a novel CAR construct targeting a unique Aspergillus fumigatus cell wall component. Through our Anti-Aspergillus fumigatus CAR cell therapy development service, the institution successfully identified multiple potential CAR targets and developed lead CAR constructs with demonstrated in vitro specificity and efficacy within a rapid 14-week timeframe, significantly accelerating their research.

Case Study Two---

A biopharmaceutical company sought to advance their anti-fungal CAR cell candidate into preclinical testing. After utilizing our service for CAR cell engineering and in vivo validation, the biopharmaceutical company successfully completed critical preclinical milestones, demonstrating significant reduction in fungal burden and improved survival in a murine model of invasive aspergillosis, paving the way for IND-enabling studies.

FAQs

Q1: What types of immune cells can be engineered using your service?

A1: Our service is highly flexible and can engineer various immune cell types, primarily T cells and Natural Killer (NK) cells, to express the anti-Aspergillus fumigatus CAR. We can discuss which cell type is most suitable for your specific project goals during your consultation.

Q2: How long does the development process for an anti-Aspergillus fumigatus CAR cell therapy typically take?

A2: The estimated timeframe for our service generally ranges from 12 to 20 weeks. This duration can vary depending on the complexity of the CAR design, the extent of preclinical validation required, and the specific antigen targets involved. We provide a detailed project timeline after initial consultation.

Q3: What are the key safety considerations for anti-Aspergillus fumigatus CAR cell therapy, and how does Creative Biolabs address them?

A3: As with any cellular therapy, potential safety considerations include cytokine release syndrome (CRS) and potential off-target effects. To reduce these risks, Creative Biolabs conducts thorough in vitro and in vivo preclinical research, which includes specificity assays and toxicity studies. Our improved CAR designs seek to be highly selective to Aspergillus fumigatus antigens while reducing interactions with host cells.

Related Services

Aside from this, Creative Biolabs offers a full array of ancillary services aimed at enhancing your research and speeding the development of breakthrough cellular immunotherapies and fungal immunology solutions:

Work with Creative Biolabs

Creative Biolabs stands at the forefront of CAR cell therapy development, offering unmatched expertise in fungal immunology and advanced cell engineering. Our commitment to innovation, coupled with our state-of-the-art platforms, ensures the highest quality and most effective solutions for your anti-fungal CAR cell therapy projects. If you want to know more about our CellRapeutics™ anti-Aspergillus fumigatus CAR cell therapy development service, please feel free to get in touch with us.

Reference

Lauruschkat, Chris D et al. "Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives." Journal of fungi (Basel, Switzerland) vol. 4,4 137. 14 Dec. 2018, DOI:10.3390/jof4040137. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.